| P50 | author | David Andes | Q75205210 |
| P2093 | author name string | Alison G Freifeld | |
| | J Ryan Bariola | |
| P2860 | cites work | Toxicodynamics of itraconazole: implications for therapeutic drug monitoring | Q43291845 |
| | Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplant center in an endemic area | Q43408814 |
| | Congestive heart failure associated with itraconazole | Q43638251 |
| | Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations | Q44038337 |
| | Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients | Q44564506 |
| | Successful treatment of relapsing disseminated coccidioidomycosis with cutaneous involvement with posaconazole | Q46401149 |
| | Successful treatment of cerebral blastomycosis with voriconazole | Q46433653 |
| | Antimycotic drugs under continuous renal replacement therapy | Q46434496 |
| | Refractory coccidioidomycosis treated with posaconazole | Q46503391 |
| | In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi | Q46595795 |
| | Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes | Q46826187 |
| | Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. | Q47779353 |
| | Cerebral blastomycosis: a case series incorporating voriconazole in the treatment regimen | Q48384500 |
| | Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole | Q72079846 |
| | Plasma itraconazole concentrations in patients with neutropenia: advantages of a divided daily dosage regimen | Q73845177 |
| | Salvage treatment of histoplasmosis with posaconazole | Q79849170 |
| | Blastomycosis in solid organ transplant recipients | Q80145622 |
| | Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America | Q81230358 |
| | Coccidioidomycosis | Q81312238 |
| | Recurrent central nervous system blastomycosis in an immunocompetent child treated successfully with sequential liposomal amphotericin B and voriconazole | Q82986914 |
| | Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole | Q83181289 |
| | Successful use of combination antifungal therapy in the treatment of coccidioides meningitis | Q83996843 |
| | Voriconazole therapeutic drug monitoring. | Q24542411 |
| | Clinical significance of the cytochrome P450 2C19 genetic polymorphism | Q28201086 |
| | Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial | Q28277029 |
| | In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans | Q28379195 |
| | Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. | Q33626342 |
| | In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum | Q33979873 |
| | Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics | Q34291656 |
| | Review of the safety and efficacy of voriconazole | Q34544679 |
| | Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America | Q34680407 |
| | In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts | Q34680661 |
| | Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis | Q36042366 |
| | Making sense of itraconazole pharmacokinetics | Q36239971 |
| | Activity of posaconazole in the treatment of central nervous system fungal infections | Q36246196 |
| | Pharmacokinetic/pharmacodynamic profile of voriconazole | Q36520587 |
| | Posaconazole therapy for chronic refractory coccidioidomycosis | Q36851052 |
| | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers | Q37115829 |
| | Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. | Q37119650 |
| | Voriconazole use for endemic fungal infections | Q37144791 |
| | Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers | Q37247780 |
| | Antifungal therapeutic drug monitoring: established and emerging indications | Q37310029 |
| | Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents | Q37441245 |
| | Blastomycosis of the central nervous system: a multicenter review of diagnosis and treatment in the modern era. | Q37694545 |
| | Adverse reactions to voriconazole. | Q38918614 |
| | A case of disseminated histoplasmosis successfully treated with the investigational drug posaconazole | Q38947833 |
| | Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice | Q39475167 |
| | Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity | Q40582555 |
| | Oral azole drugs as systemic antifungal therapy | Q40796244 |
| | Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis | Q42064852 |
| | Effect of food on the pharmacokinetics of multiple‐dose oral voriconazole | Q42284203 |
| | Safety evaluation of chronic fluconazole therapy. Fluconazole Pan-American Study Group | Q42547487 |
| | Fluconazole-induced congenital anomalies in three infants | Q42553585 |
| | Treatment of blastomycosis with higher doses of fluconazole. The National Institute of Allergy and Infectious Diseases Mycoses Study Group | Q42665247 |
| | Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients | Q42998203 |
| | Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity | Q43190645 |
| | Successful use of voriconazole for treatment of Coccidioides meningitis | Q43240160 |
| P433 | issue | 6 | |
| P304 | page(s) | 471-478 | |
| P577 | publication date | 2010-11-01 | |
| P1433 | published in | Current infectious disease reports | Q26842136 |
| P1476 | title | The role of second-generation antifungal triazoles for treatment of the endemic mycoses | |
| P478 | volume | 12 | |